SMS Pharmaceuticals Limited has informed the Exchange regarding Change in Auditors of the company.
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals reported strong FY25 results with standalone revenue of ₹78,274.81 lakhs (up 10.4% from ₹70,926.34 lakhs) and net profit of ₹6,838.12 lakhs (up 38.4% from ₹4,942.49 lakhs), with EPS rising to ₹8.07 from ₹5.84. Q4 standalone revenue was ₹24,819.56 lakhs with net profit of ₹2,062.24 lakhs (up 29.5% YoY). The Board recommended a final dividend of 40 paise (40%) per share. Statutory auditor Suryanarayana & Suresh issued an unmodified opinion. The Board also approved appointments of cost, secretarial, and internal auditors, a ₹10 crore investment in subsidiary SMS Peptides, and incorporation of a new wholly owned subsidiary for pharma manufacturing.
Strong earnings growth, healthy dividend, and a clean audit opinion are positive signals for shareholders. The new subsidiary and investment in SMS Peptides suggest business expansion, while the dilution from warrant conversion has been factored into EPS.